ClinicalTrials.gg
CompletedNCT00686855Updated Mar 20, 2014Results posted

Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease

A Phase 2 interventional study of Tacrolimus and Dexamethasone in Oral Chronic Graft-versus-host Disease, sponsored by Brigham and Women's Hospital. Completed at 5 sites in United States. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2014-03-20.

Sponsored by Brigham and Women's Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States — 48 open to participants now, 70 under way, 7 of them phase 3. Bronchiolitis Obliterans Syndrome · United States.

Enrollment
128th of 260
46 · median 45
Started
2008
with 12 others
Phase 2
79 of 300
15 open now
Registered
47th of 300
by date

Among the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, this one is the 128th largest by enrollment of the 260 interventional ones that give a count, is one of 13 that started in 2008, is one of 79 in phase 2, and was the 47th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

48 of the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to determine the effectiveness of topical steroid therapy (with a drug called dexamethasone) and topical tacrolimus therapy for the treatment of oral chronic Graft-Versus-Host Disease (cGVHD)

Read the detailed description
  • Because no one knows which study option is best, participants will be "randomized" into one of two study groups: topical dexamethasone or topical tacrolimus.
  • Participants will take the medication by mouth rinse four times a day for 5 minutes at a time. After rinsing they will spit out the medication and will not be able to eat or drink for 15 minutes.
  • Participants will also take anti-fungal medication (fluconazole) orally once a week.
  • After two weeks on study treatment, participants will have a blood drawn to monitor tacrolimus levels.
  • After the final treatment (4 weeks), participants will have the following tests and procedures: clinical examination; questionnaire; blood tests; oral culture; optional tissue biopsy.
03

Conditions studied

  • Oral Chronic Graft-versus-host Disease

Keywords

  • tacrolimus
  • dexamethasone
  • oral rinse
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with oral chronic
  • Patients 4 years of age or older
  • Stable cGVHD medication regimen for the four weeks prior to study enrollment

Exclusion criteria

Exclusion Criteria:

  • Patients already on topical or tacrolimus therapies
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Tacrolimus

    Tacrolimus Arm Closed to Accrual as of January 2012

    Drug: Tacrolimus

  • Experimental
    Dexamethasone

    Drug: Dexamethasone

Interventions

  • Tacrolimus elixir taken as an oral rinse four times a day for 4 weeks

  • Dexamethasone elixir taken as an oral rinse 4 times a day for 4 weeks

06

What researchers measure

Primary outcomes

  1. The Clinical Efficacy of Topical Steroid and Topical Tacrolimus Therapies for the Treatment of Oral cGHVD.

    Participants were given a survey at the time of screening and 4 weeks after start of therapy. The participants self-reported three symptoms of oral cGVHD: oral sensitivity, mouth pain, and mouth dryness. Each symptom was given a score ranging from 0-10, with 0 as none and 10 as the worst. Improvement in subjective scores was defined as 3 points or further reduction from pre-treatment to post-treatment assessment.

    Time frame: Participants were assessed at Baseline and 4 weeks after start of therapy

07

Results

Posted Feb 19, 2014

Participant flow

Participant flow — Overall Study
MilestoneDexamethasoneTacrolimus
Started2818
Completed2717
Not completed11
Withdrew: Lost to follow-up10
Withdrew: Progressive gvhd01

Outcome measures

PrimaryThe Clinical Efficacy of Topical Steroid and Topical Tacrolimus Therapies for the Treatment of Oral cGHVD.

Participants were given a survey at the time of screening and 4 weeks after start of therapy. The participants self-reported three symptoms of oral cGVHD: oral sensitivity, mouth pain, and mouth dryness. Each symptom was given a score ranging from 0-10, with 0 as none and 10 as the worst. Improvement in subjective scores was defined as 3 points or further reduction from pre-treatment to post-treatment assessment.

Time frame:
Participants were assessed at Baseline and 4 weeks after start of therapy
Reported as:
Number · participants
The Clinical Efficacy of Topical Steroid and Topical Tacrolimus Therapies for the Treatment of Oral cGHVD.
participantsDexamethasoneTacrolimus
Improvement in Oral Sensitivity153
Improvement in Mouth Pain112
Improvement in Mouth Dryness115
Improvement in 1 or more areas177
Improvement in 2 or more areas132
Improvement in all 3 areas71

Adverse events

Collected over Adverse events were collected during the four week peroid participants took the study treatment.. Non-serious events are listed at a 3.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dexamethasone—0/28 (0%)1/28 (3.6%)
Tacrolimus—1/18 (5.6%)1/18 (5.6%)
Most frequent serious events
Most frequent serious events
EventDexamethasoneTacrolimus
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/281/18
Most frequent other events
Most frequent other events
EventDexamethasoneTacrolimus
Infection Gr0-2 neutrophils - oral cavityInfections and infestations0/281/18
Pain - Oral CavityGeneral disorders1/280/18

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)DexamethasoneTacrolimusTotal
<=18 years000
Between 18 and 65 years221234
>=65 years6612
Age, Continuous
Age, Continuous(years)DexamethasoneTacrolimusTotal
Mean53.8 ± 11.554.9 ± 15.354.2 ± 13
Sex: Female, Male
Sex: Female, Male(Participants)DexamethasoneTacrolimusTotal
Female17623
Male111223
Region of Enrollment
Region of Enrollment(participants)DexamethasoneTacrolimusTotal
United States281846
08

Study locations

5 sites
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Children's Hospital Boston
    Boston, Massachusetts 02115, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Beth-Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Dec 2012 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2008
First posted
May 30, 2008
Start
Aug 2008
Primary completionActual
Dec 2012
CompletionActual
Mar 2013
Results first posted
Feb 19, 2014
Last update
Mar 20, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00686855
Responsible party
Nathaniel S. Treister, DMD, DMSc (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
May 30, 2008
Start date
Aug 2008
Primary completion
Dec 2012
Completion
Mar 2013
Results posted
Feb 19, 2014
Last update
Mar 20, 2014

Study contacts

Nathaniel Treister, DMD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tacrolimus · Dexamethasone

Start the discussion